March 19, 2021

Isofol receives recommendation from iDSMB to complete the AGENT study for market registration as planned with 440 patients

Link to the press release >>

November 2, 2020

Isofol announces licensing agreement for Paladin Labs Inc. to commercialize arfolitixorin in Canada

Link to the press release >>

See how arfolitixorin
works in cancer cells

See the animation >>



Startpage 2

Upcoming Events